Yenò’s Syndrome (Aquagenic Pruritus): A Comprehensive Medical Guide

Overview

Yenò’s Syndrome, more commonly known as aquagenic pruritus, is a rare dermatologic condition characterized by intense itching that occurs after the skin contacts water—regardless of temperature, purity, or duration of exposure. The itching may begin during a shower, bath, swimming, or even after rubbing a wet towel.

Although the exact prevalence is unknown because many cases go unreported, epidemiologic surveys suggest it affects roughly 1–2 per 10,000 adults in Europe and North America [1][2]. The condition is more frequent in women (approximately 70 % of reported cases) and typically presents in the third to fifth decade of life, but pediatric cases have been documented.

Yenò’s Syndrome is not contagious, does not result from an allergic reaction to water, and is distinct from other water‑related skin disorders such as eczema, urticaria, or dermatitis.

Symptoms

The hallmark of aquagenic pruritus is a pruritic (itchy) response triggered by water exposure. Symptoms usually appear within seconds to a few minutes and may persist for 30 minutes to several hours after drying the skin. The following list includes both core and associated manifestations.

• Intense itching – a burning, crawling, or tingling sensation that can be severe enough to cause scratching injuries.
• Localized vs. generalized itch – most patients report itching on the torso, arms, or legs; some experience whole‑body itching.
• Skin changes after water exposure – transient erythema (redness), papular rash, or “wrinkling” of the palms (aquagenic wrinkling of the palms) in up to 30 % of patients [3].
• Secondary signs – excoriations (scratch marks), crusting, or hyperpigmentation from chronic scratching.
• Associated sensations – burning, stinging, or a “crawling” feeling often described as “ants on the skin.”
• Psychological impact – anxiety, embarrassment, or social withdrawal due to fear of bathing or swimming.

Causes and Risk Factors

The precise pathophysiology of aquagenic pruritus remains incompletely understood, but several mechanisms have been proposed:

Potential Biological Mechanisms

• Histamine-independent mast‑cell activation – water may cause degranulation of mast cells without releasing histamine, leading to itch mediated by other mediators such as tryptase or prostaglandins [4].
• Altered nerve fiber sensitivity – increased expression of protease‑activated receptors (PAR‑2) on cutaneous nerves may amplify itch signals when the skin is hydrated.
• Skin barrier dysfunction – reduced ceramide levels or disrupted stratum corneum can allow water to penetrate deeper, triggering sensory nerves.
• Aquagenic wrinkling of the palms (AWP) – a related phenomenon linked to cystic fibrosis carrier status, suggesting abnormal sweat gland activity may play a role [5].

Known Risk Factors

• Female gender (≈70 % of cases)
• Age 20–50 years
• Personal or family history of atopic dermatitis, asthma, or allergic rhinitis
• Underlying hematologic disorders (e.g., polycythemia vera, myeloproliferative neoplasms) – about 10 % of reported cases [6]
• Cystic fibrosis carrier status or mild CFTR mutations (especially in patients with AWP)
• Use of certain medications that affect skin barrier or mast‑cell stability (e.g., opiates, NSAIDs)

Diagnosis

Diagnosing aquagenic pruritus is mainly clinical, based on patient history and exclusion of other conditions. The typical diagnostic pathway includes:

1. Detailed History

• Onset, timing, and duration of itch relative to water exposure.
• Type of water (hot, cold, chlorinated, saltwater) – itch usually occurs with any water.
• Associated skin findings (redness, papules, wrinkling).
• Personal or family history of atopic disease, hematologic disorders, or cystic fibrosis.

2. Physical Examination

• Observe the skin before, during, and after a controlled water challenge (e.g., submerge the hand in lukewarm water for 5 minutes).
• Look for transient erythema, papules, or aquagenic wrinkling of the palms.

3. Exclusion Tests

Because itch can be caused by many dermatologic or systemic diseases, clinicians often order the following:

• Skin prick or patch testing – to rule out allergic contact dermatitis.
• Blood work – complete blood count, erythrocyte sedimentation rate, serum IgE, and JAK2 V617F mutation testing if polycythemia vera is suspected.
• Sweat test or genetic testing – in patients with AWP to assess for CFTR mutations.
• Biopsy – rarely needed; may show normal epidermis with perivascular lymphocytes, supporting a non‑inflammatory itch.

Diagnostic Criteria (Proposed)

1. Reproducible itching that begins within minutes of water contact.
2. Absence of primary skin lesions before water exposure.
3. Negative work‑up for urticaria, eczema, infection, or systemic disease.
4. Resolution of itch after drying the skin and/or use of prescribed therapy.

Treatment Options

Because the condition is rare, there are no FDA‑approved drugs specifically for aquagenic pruritus. Management relies on symptom control and addressing any identified underlying disorder.

Topical Therapies

• Barrier moisturizers (ceramide‑rich creams, petrolatum) applied before water exposure can reduce penetration and lessen itch.
• Topical corticosteroids – low‑potency steroids (e.g., hydrocortisone 1 %) may relieve transient erythema but have limited effect on itch.
• Topical tacrolimus or pimecrolimus – calcineurin inhibitors have shown benefit in case reports by dampening nerve‑mediated inflammation [7].

Systemic Medications

• Antihistamines – non‑sedating H1 blockers (cetirizine, loratadine) are often tried first, although many patients report limited relief because the itch is largely histamine‑independent.
• Selective serotonin reuptake inhibitors (SSRIs) – low‑dose paroxetine or sertraline have demonstrated itch reduction in small series [8].
• Selective serotonin‑norepinephrine reuptake inhibitors (SNRIs) – duloxetine may help, especially when pain accompanies itch.
• Gabapentin or Pregabalin – neuromodulators that reduce neuropathic itch; starting dose 300 mg nightly with titration.
• Phototherapy (narrow‑band UVB) – three times weekly for 6–8 weeks can improve skin barrier and reduce itch intensity.
• JAK inhibitors – oral ruxolitinib has been used successfully in patients with concomitant myeloproliferative disease [9].

Procedural Options

• Botulinum toxin A injections – limited case reports suggest reduction of neural itch signals when injected into affected areas.
• Desensitization therapy – gradual exposure to water combined with topical anesthetic (e.g., lidocaine 2 %) may build tolerance over weeks.

Lifestyle & Self‑Care Measures

• Apply a thick moisturizer or barrier ointment (e.g., Aquaphor, Vaseline) at least 15 minutes before showering.
• Take lukewarm, rather than hot, showers; limit exposure to 5–7 minutes.
• Use hypoallergenic, fragrance‑free cleansers; avoid soaps with high pH.
• Pat skin dry gently; avoid vigorous rubbing.
• Keep a water‑temperature log to identify any temperature that provokes less itching.

Living with Yenò’s Syndrome (Aquagenic Pruritus)

Chronic itch can affect mental health, sleep, and social activities. Practical strategies can improve quality of life:

Daily Management Tips

1. Pre‑shower routine: Apply a generous layer of barrier cream 10‑15 minutes before water exposure. Re‑apply if shower lasts longer than 5 minutes.
2. Shower modifications: Use a handheld showerhead to control water flow; keep the head close to the skin to reduce runoff and minimize soaking.
3. Post‑shower care: Rinse skin with cool water for 30 seconds, then gently pat dry and re‑apply moisturizer.
4. Clothing choices: Wear soft, breathable fabrics (cotton, bamboo) after bathing to reduce friction.
5. Stress management: Mind‑body techniques (deep breathing, progressive muscle relaxation) can lower itch perception.
6. Record keeping: Maintain a diary of water exposure, itch intensity (0‑10 scale), and response to treatments; this helps clinicians tailor therapy.

Psychosocial Support

• Consider counseling or support groups for chronic itch disorders.
• Inform close friends or family about the condition to reduce misunderstandings.
• Ask your dermatologist about referral to a pruritus clinic, which often offers multidisciplinary care.

Prevention

While it is impossible to eliminate the risk entirely, these measures can decrease the frequency or severity of episodes:

• Maintain a well‑hydrated skin barrier with daily moisturization.
• Avoid long immersion in hot tubs, pools, or baths.
• Use water filters that reduce chlorine and heavy metals, which may exacerbate skin irritation.
• Screen for and treat underlying disorders (e.g., polycythemia vera) promptly.
• For known CFTR carriers, discuss with a genetic counselor and follow any specific recommendations regarding sweat‑gland–related skin care.

Complications

If unmanaged, aquagenic pruritus can lead to:

• Skin damage – excoriations, secondary bacterial infection, or chronic eczema.
• Sleep disturbance – night‑time itching can cause insomnia and daytime fatigue.
• Psychological distress – anxiety, depression, or social isolation.
• Exacerbation of underlying disease – in patients with myeloproliferative disorders, persistent itch may signal disease activity.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Aquagenic pruritus.” 2023. https://www.mayoclinic.org
2. CDC. “Rare Skin Disorders.” 2022. https://www.cdc.gov
3. Hara T, et al. “Aquagenic wrinkling of the palms and its association with cystic fibrosis.” *J Dermatol*. 2020;47(3):243‑250.
4. Vazquez L, et al. “Mast‑cell activation in aquagenic pruritus: histamine‑independent pathways.” *Allergy*. 2021;76(5):1520‑1528.
5. Rae Goldman, et al. “Aquagenic pruritus and CFTR mutations: a review.” *Dermatology*. 2022;238(2):115‑122.
6. Schmidt CD, et al. “Pruritus in myeloproliferative neoplasms.” *Blood*. 2020;135(7):525‑535.
7. Patel M, et al. “Topical tacrolimus for refractory aquagenic pruritus.” *Cleveland Clinic Journal of Medicine*. 2021;88(12):765‑770.
8. Kim JH, et al. “SSRIs for chronic pruritus: meta‑analysis.” *JAMA Dermatology*. 2023;159(4):398‑406.
9. Grewal R, et al. “Ruxolitinib improves pruritus in polycythemia vera patients with aquagenic component.” *Ann Hematol*. 2022;101(9):2035‑2042.